Earnings Call Intelligence Subscribe
Home › Call Sheets › VRTX › Q2'26
Call sheet · Q2'26

Vertex Pharmaceuticals (VRTX)

Q2'26 earnings call · held August 3, 2026 · compared with the Q1'26 call · management-credibility review
6/12
Disclosure score
2 high, 3 medium, 1 low flags
Financial quality
Bottom line
Market will focus on the 12% top‑line beat, but the real story is Casgevi’s 77% revenue surge - a quiet driver of non‑CF growth. The headline looks good, yet the binding constraint is the renal launch capacity: a specialty‑size nephrology force and manufacturing ramp‑up that could delay the expected $500 M+ contribution from non‑CF assets. Management’s vague “later this year” on the Type O T1D timeline signals execution risk. My view changes if cash‑flow from operations does not improve in the next quarter or if the renal field force headcount lags the required 80% IGAN coverage.

The 30-second version

  • Sleeper story: Casgevi’s revenue acceleration is the hidden growth engine
  • Obvious headline - 12% revenue growth - masks a binding constraint in renal launch capacity

What changed this quarter

MetricQ1'26Q2'26Change
Total revenue$2.99 B, +8% YoY (Q1)$3.30 B, +12% YoY (Q2)+31 billion (+10% YoY acceleration)
Casgevi revenue$43 M (Q1)$76 M (Q2)+77% YoY, strong momentum
Genavix revenue$29 M (Q1)$50 M (Q2)+72% YoY, driven by channel build
Gross marginJust under 86% (Q1 implied)85.6% (Q2)step‑down of ~0.4 pts due to mix shift
Non‑GAAP SG&A expense+30% YoY (Q1)+45% YoY (Q2)Higher commercial spend on renal & pain
Non‑GAAP R&D expense-2% YoY (Q1)+1% YoY (Q2)Modest increase, reflects trial spend
Cash on hand$13.0 B (Q1)$13.6 B (Q2)+$600 M, modest increase
Share repurchase~741 k shares Q1~1 M shares Q2Accelerated buy‑back
Full‑year revenue guidance$12.95‑$13.10 B (Q1)$13.1‑$13.2 B (Q2)Guidance raised, but still includes FX benefit
Non‑GAAP effective tax rate19.6% (Q1)21.1% (Q2)Increase reflects higher income and one‑time items

Accountability tracked

2 new promises made1 narrative shift flagged1 prior promise scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full VRTX Q2'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.